New therapeutic agents for the treatment of NIDDM

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue 2, 1996, Pages 93-101

  Kuehnle, H F ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Carbonic acid derivatives; Insulin resistance; NIDDM; Pathophysiology; Thiazolidindiones; Treatment

Indexed keywords

7 (4 CHLOROPHENYL) 2 (4 METHYLPHENOXY)HEPTANOIC ACID; ANTIDIABETIC AGENT; BM 170249; CIGLITAZONE; ENGLITAZONE; INSULIN; METFORMIN; PIOGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG TOLERABILITY; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; META ANALYSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REVIEW; VASCULAR DISEASE;

EID: 0029920573     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211429     Document Type: Review

References (54)

1. Akanuma Y, Kosaka K, Kuzuya T, Shimizu N, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by diet alone - A dose finding study by dose increasing method. J Clin Ther Med 9 (2-3): 19-37, 1993.
2. Akanuma Y, Kosaka K, Kuzuya T, Shimizu N, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by sulfonylureas - A dose finding study by dose increasing method. J Clin Ther Med 9 (S-3): 39-60, 1993.
3. Apweiler R, Kühnle HF, Ritter G, Schell R, Freund P: Effect of the new oral antidiabetic agent (-)-BM 13.0913. Na on insulin resistance in lean and obese zucker rats. Metabolism 44, No. 5: 577-583, 1995.
4. Bader S, Kiehn R, Häring HU: Effekt von CS045 auf die Kinaseaktivität des Insulinrezeptors im Skelettmuskel insulin-resistenter Zucker-Ratten. Diabetes und Stoffwechsel 2: 56-61, 1993.
5. Bar-Tana J, Ben-Shoshan S, Blum J, Migron Y, Hertz R, Pill J, G. Rose-Khan G, Witte EC: Synthesis and Hypolipidemic and antidiabetogenic activities of β,β,β,β,-Tetrasubstituted, Long-Chain Dioic acids. J Med Chem 32: 2072-2084, 1989.
6. Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states, sequence of events leading to non-insulin dependent diabetes mellitus. J Clin Invest 94: 1714-1721, 1994.
7. Chang AY, Wyse BM, Gilchrist BJ: Ciglitazone, a new hypoglycemic agent II. effect of glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -+/? mice. Diabetes 32: 839-845, 1983.
8. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR: Ciglitazone, a new hypoglycemic agent I. studies in ob/ob and db/db mice, diabetic chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 32, 830-838, 1983.
9. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39, No. 10: 1056-1062, 1990.
10. Diani AR, Peterson T, Sawada GA, Wyse BM. Gilchrist BJ, Hearron AE, Chang AY: Ciglitazone, a new hypoglycaemic agent. 4. effect on pancreas islets of C57BL/ 6J-ob/ob and C57BL/KsJ-db/db mice. Diabetologia 27: 225-234, 1984.
11. Doebber T, Wu M, Ventre J: Pioglitazone increases insulin sensitivity in insulin-resistant rats and control rats as measured by the glucose clamp. Diabetes 41, No. 1: 76A, 1992.
12. Doebber T, Wu M, Ventre J: Determination of the tissues responsible for insulin resistance in zucker diabetic fatty rats as measured by the glucose clamp technique: effect of pioglitazone. Diabetes 42, No. 1: 66A, 93-31353, 1993.
13. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L: Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. N Engl J Med 321: 337-343, 1989.
14. Freund P, Kühnle HF, Wolff HP, Apweiler R: Ein neues orales Antidiabetikum mit Wirkung auf die periphere Insulinresistenz. Diabetes Stoffw 1: 102-106, 1992.
15. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzucki Z: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a new antidiabetic agent. Diabetes 32: 804-810, 1983.
16. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Charakterization of a new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and zucker fatty rats. Diabetes 37 (11): 1549-58, 1988.
17. Fujiwara T, et al: Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 40, No. 11: 1213-1218, 1991.
18. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H: Suppression of Hepatic Gluconeogenesis in Long-Term Troglitazone Treated Diabetic KK and C57BL/KsJ-db/db Mice. Metabolism 44 (No 4): 486-490, 1995.
19. Gibbs EM, Genereux PE, Keutter DK, et al: A novel antidiabetic agent CP 68.722 increases levels of glucose transport and glucose transporter protein in 3T3L-1 adipocytes. Diabetologia 32: (abstr 491A), 1989.
20. Giraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39, No. 10: 1056-1062, 1990.
21. Granner DK, O'Brien RM: Molecular physiology and genetics of NIDDM. Diabetes Care 15: 369-388, 1992.
22. Gulli G, Ferrannini ETL, Stern M, Haffner S, DeFronzo R: The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41, 1575-1587, 1992.
23. Häring HU, Mehnert H: Pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: Candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle Diabetologia 36: 176-182, 1993.
24. Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. populations aged 20-74 yr. Diabetes 36: 523-534, 1987.
25. Hofmann C, Lorenz K, Colca JR: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129, No. 4: 1915-1925, 1991.
26. Hofmann C, Lorenz K, Palazuk BJ, Colca JR: Pioglitazone-treatment sensitized diabetic rats to insulin inhibition of PEPCK expression in liver. Diabetes 42, No. 1: 169 A, 1993.
27. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim.-Forsch./Drug Res. 40 (I), Nr. 2: 156-162, 1990.
28. Iwamoto Y, et al: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14, No. 11: 1083-1086, 1991.
29. Kobayashi M, Iwanishi M, Kogawa K, Shigeta Y: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 412: 476-483, 1992.
30. Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by diet alone - A double-blind, placebo-controlled study. J Clin Ther Med 9 (S-3): 61-93, 1993.
31. Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by sulfonylureas - A double-blind, placebo-controlled study. J Clin Ther Med 9 (S-3): 95-126, 1993.
32. Kreutter DK, Adrews KM, Gibbs EM, et al: Insulin-like activity of new antidiabetic agent CP 68.722 in 3T3-L1 adipocytes. Diabetes 39: 1414-1419, 1990.
33. Kuzuya T, et al: A pilot clinical trial of a new oral hypoglycemic agent, S-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Research and Clinical Practice 11: 147-154, 1991.
34. Kuzuya T, Kosaka K, Takebe K, Iwamoto Y, Yamanouchi S, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: An early phase II clinical trial of a new oral hypoglycemic drug, CS-045, in patients with non-insulin dependent diabetes mellitus: J Clin Ther Med 9 (S-3):3-18, 1993.
35. Lillioja S, Mott DM, Spraul M: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 329: 1988-1992, 1993.
36. Martin BC, Warram JH, Krolewski RN, Soeldner JS, Kahn CR: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340: 925-929, 1992.
37. Masuda H., Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y: Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38: 24-30, 1995.
38. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. The New Engl J of Med 3: 1188-1193, 1994.
39. Olivarius FN: Diabetic complications presenting in 1360 newly diagnosed middle-aged and elderly diabetics. 13th WONCA World Conference on Family Medicine (Abstract), 1992.
40. Pill J, Freund P, Kuehnle HF, Bodkin N, Hansen B: BM 17.0249, a agent with antidiabetic potency: pharmacodynamic and pharmacokinetic investigations in various species. Abstract 14, p. 29: 29th Research Symposium and the International Congress on Obesity Satellite Conference, American Diabetes Association, Boston, August 25-27, 1994.
41. Reaven GM: Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metabolism, Reviews 9, (Supplement 1): 5-12, 1993.
42. Skarfors ET, Selenus KI, Lithell HO: Risk factors for developing non-insulin dependent diabetes mellitus: a 10-year follow-up of men in Uppsala. Br Med J 303: 755-760, 1991.
43. Sohda T, Mizuno K, Tawada H, Sugiyama Y, Fujita T, Kawamatsu Y: Studies on antidiabetic agents. I. synthesis of 5-[4-(2-Methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. Chem Pharm Bull 30 (10): 3563-3573, 1982.
44. Sohda T, Meguro K, Kawamatsu Y, Ikeda H, Fujita T: A new antidiabetic agent, AD-4833, and structure-activity relationships of 5-[4-(pyridyl-alkoxy)benzyl]-2,4-thiazolidinediones. J Pharm Sci 76: 173, 1987.
45. Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H: Studies on antidiabetica agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)bezyi]-2,4-thiazolidmediones. Arzneim.-Forsch./ Drag Res. 40 (I), Nr. 1: 37-42, 1990.
46. Stevenson RW, et al: Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 39: 1218-1227, 1990.
47. Stevenson RW, et al: Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 40, No. 12: 1268-1274, 1991.
48. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin dependent diabetes mellitus. The New Engl J of Med: 550-554, 1995.
49. Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T: Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim.-Forsch./Drug Res. 40 (I), Nr. 3: 263-267, 1990.
50. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15, 2: 193-203, 1992.
51. United Kingdom prospective diabetes study group. Br Med J 310: 83-88, 1995.
52. Vaag A, Henriksen JE, Beck-Nielsen H: Decreased insulin activation of glycogen synthase in skeletal muscles in young monobese caucasian first-degree relatives of patients with non-insulin dependent diabetes mellitus. J Clin Invest 89: 782-788, 1992.
53. Wyse BM, Burr JE, Dinh DM, Dailley CF: A comparison of the effects of pioglitazone with CS-045 in C57BL/6J-ob/ob mice. Diabetes 39, No. 1: 212 A, 1990.
54. Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kutumada, T, Hasegawa K, Horikoshi H: Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32 (2): 421-428, 1989.